Combating the global medical challenge caused by Gram-negative 'superbugs': from redeveloping the polymyxins to discovering novel antibiotics

应对革兰氏阴性“超级细菌”造成的全球医学挑战：从重新开发多粘菌素到发现新型抗生素

• 批准号: nhmrc : 1002788
• 负责人: Prof Jian Li
• 金额: $ 25.01万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Research Fellowships
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/combating-global-medical-novel-antibiotics/108860
• 关键词: Combating; global; medical; challenge; caused

Bacterial �superbugs� are becoming a major global medical challenge. Polymyxins are the last-line antibiotics against Gram-negative �superbugs� but with little pharmacological information available. I am an antimicrobial pharmacologist specialised in re-developing polymyxins, and discovering novel antibiotics against these very troublesome bacteria. My research targets the _Bad Bugs, No Drugs� disaster highlighted by the Infectious Diseases Society of America and the World Health Organization.

细菌“超级细菌”正在成为一个重大的全球医学挑战。多粘菌素是对抗革兰氏阴性“超级细菌”的最后一线抗生素，但几乎没有药理学信息。我是一名抗微生物药理学家，专门研究多粘菌素的再开发，并发现针对这些非常棘手的细菌的新型抗生素。我的研究目标是美国传染病协会和世界卫生组织强调的“坏虫子，没有药物”灾难。